UZH-Logo

Maintenance Infos

A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma- A review of 12 years' experience


Opitz, Isabelle; Friess, Martina; Kestenholz, Peter; Schneiter, Didier; Frauenfelder, Thomas; Nguyen-Kim, Dan Linh; Seifert, Burkhardt; Hoda, Mir Alireza; Klepetko, Walter; Stahel, Rolf A; Weder, Walter (2015). A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma- A review of 12 years' experience. Journal of Thoracic Oncology, 10(11):1634-1641.

Abstract

INTRODUCTION Treatment of malignant pleural mesothelioma (MPM) remains a clinical challenge. The aim of this study was to identify selection factorsfor allocation of MPM patients to multimodal therapy based on survival data from 12 years of experience. METHODS Eligible patients had MPM of all histological subtypes with clinical stage T1-3 N0-2 M0. Induction chemotherapy consisted of cisplatin/gemcitabine (cis/gem) orcisplatin/pemetrexed (cis/pem), followed by extrapleural pneumonectomy (EPP).Multivariate analysis was performed to assess independent prognosticators for overall survival (OS). A Multimodality Prognostic Scorewasdeveloped based on clinical variablesavailable before surgery. RESULTS From May 1999 to August 2011, 186 MPM patients were intended to be treated with induction chemotherapy followed by EPP. Hematologic toxicity was significantly less frequent after cis/pemcompared to cis/gem, but no difference in response or OS between the regimens.128 patients underwent EPP with a30-day mortalityof4.7%. 52% percent of the patients received adjuvant radiotherapy. The median OSof patients undergoing EPP was significantly longer with 22months (95%CI:20-24) as compared to 11 months (9-12) for patients treated without EPP.Aprognostic score was defined considering tumor volume,histology, CRP,andresponsetochemotherapythat identified patient groupsnot benefittingfrom multimodality treatmentwhich was confirmed in an independent cohort. CONCLUSION Patients receiving induction chemotherapy followed by EPP for MPM of all histological subtypes and irrespective of nodal statusshowed a median survival of 22months. A prognostic score is proposed to help patient allocation for surgery after validation in an independent cohort.

Abstract

INTRODUCTION Treatment of malignant pleural mesothelioma (MPM) remains a clinical challenge. The aim of this study was to identify selection factorsfor allocation of MPM patients to multimodal therapy based on survival data from 12 years of experience. METHODS Eligible patients had MPM of all histological subtypes with clinical stage T1-3 N0-2 M0. Induction chemotherapy consisted of cisplatin/gemcitabine (cis/gem) orcisplatin/pemetrexed (cis/pem), followed by extrapleural pneumonectomy (EPP).Multivariate analysis was performed to assess independent prognosticators for overall survival (OS). A Multimodality Prognostic Scorewasdeveloped based on clinical variablesavailable before surgery. RESULTS From May 1999 to August 2011, 186 MPM patients were intended to be treated with induction chemotherapy followed by EPP. Hematologic toxicity was significantly less frequent after cis/pemcompared to cis/gem, but no difference in response or OS between the regimens.128 patients underwent EPP with a30-day mortalityof4.7%. 52% percent of the patients received adjuvant radiotherapy. The median OSof patients undergoing EPP was significantly longer with 22months (95%CI:20-24) as compared to 11 months (9-12) for patients treated without EPP.Aprognostic score was defined considering tumor volume,histology, CRP,andresponsetochemotherapythat identified patient groupsnot benefittingfrom multimodality treatmentwhich was confirmed in an independent cohort. CONCLUSION Patients receiving induction chemotherapy followed by EPP for MPM of all histological subtypes and irrespective of nodal statusshowed a median survival of 22months. A prognostic score is proposed to help patient allocation for surgery after validation in an independent cohort.

Citations

3 citations in Web of Science®
6 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

42 downloads since deposited on 02 Sep 2015
40 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Diagnostic and Interventional Radiology
04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:27 August 2015
Deposited On:02 Sep 2015 14:30
Last Modified:05 Apr 2016 19:23
Publisher:Lippincott Williams & Wilkins
ISSN:1556-0864
Publisher DOI:https://doi.org/10.1097/JTO.0000000000000661
PubMed ID:26317916

Download

[img]
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations